Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma

Summary

The primary objective is to determine the maximum tolerated dose of SAR3419 and to characterize the dose limiting toxicity(ies). Secondary objectives are to determine the anti-lymphoma activity, the global safety and the PK profile.

Timeline

Start

2007-10

Primary completion

2012-01

Completion

2012-01

Outcome

Met primary endpoint

release “establish the MTD of SAR3419 when administered once every three weeks. This was determined to be 160 mg/m 2 .” abbvie.com ↗

Drugs

Indications